Curative Biotechnology, Inc. (CUBT)

Market Cap	7.29M -33.9%
Revenue (ttm)	n/a
Net Income	-2.84M
EPS	-0.42
Shares Out	7.15M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,634
Average Volume	108,175
Open	1.033
Previous Close	1.185
Day's Range	0.990 - 1.050
52-Week Range	0.003 - 1.020
Beta	1.41
RSI	43.17
Earnings Date	Apr 15, 2026

About Curative Biotechnology

Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. The company has a licen...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1995
• Employees: 4
• Stock Exchange: OTCMKTS
• Ticker Symbol: CUBT